STACY SHARP: Open Payments
NPI 1407509219 · STURGIS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 46 payments from 18 companies in 2025. Trend: 2023 $536 · 2024 $730 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $291 |
| AstraZeneca Pharmaceuticals LP | 2 | $152 |
| Novo Nordisk Inc | 4 | $94 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| Verona Pharma, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
Products named: CAPLYTA, AIRSUPRA, Wegovy, Auvelity, Kerendia, Ohtuvayre, MOUNJARO, GVOKE HYPOPEN.
Industry payments across MI — which companies pay providers there.
